MA54200A - Procédé industriel pour la préparation d'estétrol de pureté élevée - Google Patents

Procédé industriel pour la préparation d'estétrol de pureté élevée

Info

Publication number: MA54200A
Authority: MA; Morocco
Prior art keywords: estetrol; preparation; high purity; industrial process; industrial
Prior art date: 2019-09-03

Application number

MA054200A

Other languages

English (en)

Other versions

MA54200B1 (fr

Inventor

Ildikó Bacsa

Róbert Lovas

Sándor Mahó

Beatrix Mayer

Original Assignee

Richter Gedeon Nyrt

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2019-09-03

Filing date

2020-09-02

Publication date

2022-04-27

2020-09-02 Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt

2022-04-27 Publication of MA54200A publication Critical patent/MA54200A/fr

2023-02-28 Publication of MA54200B1 publication Critical patent/MA54200B1/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J75/00—Processes for the preparation of steroids in general
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0074—Esters
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Immunology (AREA)
Gynecology & Obstetrics (AREA)
Dermatology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Transplantation (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

MA54200A 2019-09-03 2020-09-02 Procédé industriel pour la préparation d'estétrol de pureté élevée MA54200B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
HU1900315A HU231240B1 (hu)	2019-09-03	2019-09-03	Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
PCT/IB2020/058148 WO2021044302A1 (fr)	2019-09-03	2020-09-02	Procédé industriel pour la préparation d'estétrol de pureté élevée

Publications (2)

Publication Number	Publication Date
MA54200A true MA54200A (fr)	2022-04-27
MA54200B1 MA54200B1 (fr)	2023-02-28

Family

ID=89992977

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA54200A MA54200B1 (fr)	2019-09-03	2020-09-02	Procédé industriel pour la préparation d'estétrol de pureté élevée

Country Status (33)

Country	Link
US (1)	US11633406B2 (fr)
EP (1)	EP3877395B1 (fr)
JP (1)	JP7265087B2 (fr)
KR (1)	KR102871606B1 (fr)
CN (1)	CN114302889B (fr)
AU (1)	AU2020343497B2 (fr)
CA (1)	CA3147815C (fr)
CL (1)	CL2022000492A1 (fr)
CO (1)	CO2022003769A2 (fr)
CU (1)	CU24692B1 (fr)
DK (1)	DK3877395T3 (fr)
EC (1)	ECSP22022403A (fr)
ES (1)	ES2855923T3 (fr)
FI (1)	FI3877395T3 (fr)
GE (1)	GEP20247626B (fr)
HR (1)	HRP20230230T1 (fr)
HU (2)	HU231240B1 (fr)
IL (1)	IL290973B2 (fr)
JO (1)	JOP20220041A1 (fr)
LT (1)	LT3877395T (fr)
MA (1)	MA54200B1 (fr)
MD (1)	MD3877395T2 (fr)
MX (1)	MX2022002603A (fr)
MY (1)	MY206905A (fr)
NZ (1)	NZ786568A (fr)
PE (1)	PE20221418A1 (fr)
PH (1)	PH12022550388A1 (fr)
PL (1)	PL3877395T3 (fr)
PT (1)	PT3877395T (fr)
RS (1)	RS63966B1 (fr)
SI (1)	SI3877395T1 (fr)
WO (1)	WO2021044302A1 (fr)
ZA (1)	ZA202203557B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2603868B (en) *	2019-09-27	2023-10-11	Ind Chimica Srl	Process for preparing (15ALPHA,16ALPHA,17BETA)-ESTRA-1,3,5(10)-TRIENE-3,15,16,17-tetrol monohydrate (estetrol monohydrate) and intermediates of said process
DE112021008305T5 (de) *	2021-10-01	2024-07-25	Industriale Chimica S.R.L.	VERFAHREN ZUR HERSTELLUNG VON (15α,16α,17β)-ESTRA-1,3,5(10)-TRIENE-3,15,16,17-TETROL (ESTETROL) UND ESTETROL-MONOHYDRAT
AU2023428138A1 (en) *	2023-02-02	2025-09-04	Industriale Chimica S.R.L.	PROCESS FOR PREPARING (15α,16α,17β)-ESTRA-1,3,5(10)-TRIENE-3,15,16,17-TETROL (ESTETROL) MONOHYDRATE
CN117088928B (zh) *	2023-08-16	2025-09-09	湖北共同甾体药物研究院有限公司	用于制备高纯度雌四醇的工艺
CN119569803B (zh) *	2023-09-05	2025-09-16	秦皇岛紫竹药业有限公司	一种制备高纯度雌四醇的方法
HUP2400151A1 (hu)	2024-02-28	2025-09-28	Richter Gedeon Nyrt	Ösztetrol-monohidrát kristályosítási eljárás

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1260225A1 (fr)	2001-05-18	2002-11-27	Pantarhei Bioscience B.V.	Compositions pharmaceutiques pour le traitement hormonal substitutif
PT1390040E (pt)	2001-05-18	2007-04-30	Pantarhei Bioscience Bv	Composição farmacêutica para ser utilizado na terapia hormonal de substituição.
ES2337129T3 (es)	2001-05-23	2010-04-21	Pantarhei Bioscience B.V.	Sistema de administracion de medicamento comprendiendo un estrogeno tetrahidroxilado para el uso en la anticoncepcion hormonal.
EP1390042B1 (fr)	2001-05-23	2007-11-28	Pantarhei Bioscience B.V.	Systeme d'administration de medicament comprenant un oestrogene tetrahydroxyle destine a une contraception hormonale
US8026228B2 (en)	2001-11-15	2011-09-27	Pantarhei Bioscience B.V.	Estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
CN100352445C (zh)	2002-06-11	2007-12-05	潘塔希生物科学股份有限公司	一种皮肤护理组合物及其用途
PT1511496E (pt)	2002-06-11	2007-01-31	Pantarhei Bioscience Bv	Método para tratamento ou prevenção de doenças mediadas pelo sistema imunitário e formulação farmacológica para utilização nas mesmas
SI1526856T1 (sl)	2002-07-12	2008-04-30	Pantarhei Bioscience Bv	Farmacevtski sestavek, ki obsega estetrolne derivate za uporabo pri zdravljenju raka
SI1556058T1 (sl)	2002-10-23	2008-02-29	Pantarhei Bioscience Bv	Farmacevtski sestavki, ki obsegajo estetrolne derivate, za uporabo pri zdravljenju raka
AU2003279624A1 (en) *	2002-11-08	2004-06-07	Pantarhei Bioscience B.V.	Synthesis of estetrol via estrone derived steroids
WO2007081206A1 (fr)	2006-01-09	2007-07-19	Pantarhei Bioscience B.V.	Procédé de traitement d'un trouble vasculaire aigu
ATE473746T1 (de)	2007-01-08	2010-07-15	Pantarhei Bioscience Bv	Verfahren zur behandlung oder prävention von unfruchtbarkeit bei weiblichen säugern und pharmazeutisches kit zur anwendung dieses verfahrens
EP2383279A1 (fr)	2011-07-19	2011-11-02	Pantarhei Bioscience B.V.	Procédé de préparation d'estetrol
PL2741824T3 (pl)	2011-08-11	2018-03-30	Estetra S.P.R.L.	Zastosowanie estetrolu jako środka antykoncepcji awaryjnej
RS55231B1 (sr)	2011-10-07	2017-02-28	Estetra Sprl	Postupak proizvodnje estetrola
EP2653163A1 (fr)	2012-04-19	2013-10-23	Université de Liège	Constituants estrogènes pour l'utilisation dans le traitement de troubles neurologiques
WO2013034780A2 (fr)	2012-12-20	2013-03-14	Crystal Pharma, S.A.U.	Procédé de préparation de l'estétrol et de composés analogues
EP3046928B1 (fr) *	2013-09-18	2017-02-08	Crystal Pharma, S.A.U.	Procédé de préparation d'estetrol
JP6447931B2 (ja)	2013-12-12	2019-01-09	ドネスタバイオサイエンスビー．ブイ．ＤｏｎｅｓｔａＢｉｏｓｃｉｅｎｃｅＢ．Ｖ．	エステトロール成分を含有する口腔内崩壊固体単位剤形
LT3310345T (lt)	2015-06-18	2021-06-25	Estetra Sprl	Burnoje disperguojama tabletė, turinti estetrolio
LT3310346T (lt)	2015-06-18	2021-06-10	Estetra Sprl	Burnoje disperguojama tabletė, turinti estetrolio
DK3701944T3 (da)	2015-06-18	2022-03-14	Estetra Srl	Oro-dispergerbar doseringsenhed indeholdende en estetrolkomponent
KR102712911B1 (ko)	2016-08-05	2024-10-04	에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼	월경통 및 생리통의 관리방법
CA3041016C (fr)	2016-10-28	2023-09-05	Estetra Sprl	Methode de prise en charge de la dysmenorrhee et des douleurs menstruelles
PL3661520T3 (pl)	2017-08-01	2022-03-28	Fund Sa	Terapia adiuwantowa do stosowania w leczeniu raka prostaty
SG11202007163WA (en)	2018-02-07	2020-08-28	Estetra Sprl	Contraceptive composition with reduced cardiovascular effects
GB2603868B (en)	2019-09-27	2023-10-11	Ind Chimica Srl	Process for preparing (15ALPHA,16ALPHA,17BETA)-ESTRA-1,3,5(10)-TRIENE-3,15,16,17-tetrol monohydrate (estetrol monohydrate) and intermediates of said process

2019
- 2019-09-03 HU HU1900315A patent/HU231240B1/hu unknown
2020
- 2020-09-02 KR KR1020227010919A patent/KR102871606B1/ko active Active
- 2020-09-02 HU HUE20768398A patent/HUE061427T2/hu unknown
- 2020-09-02 SI SI202030156T patent/SI3877395T1/sl unknown
- 2020-09-02 EP EP20768398.8A patent/EP3877395B1/fr active Active
- 2020-09-02 IL IL290973A patent/IL290973B2/en unknown
- 2020-09-02 MD MDE20210894T patent/MD3877395T2/ro unknown
- 2020-09-02 CN CN202080061521.1A patent/CN114302889B/zh active Active
- 2020-09-02 CA CA3147815A patent/CA3147815C/fr active Active
- 2020-09-02 PL PL20768398.8T patent/PL3877395T3/pl unknown
- 2020-09-02 ES ES20768398T patent/ES2855923T3/es active Active
- 2020-09-02 US US17/639,206 patent/US11633406B2/en active Active
- 2020-09-02 NZ NZ786568A patent/NZ786568A/en unknown
- 2020-09-02 GE GEAP202015920A patent/GEP20247626B/en unknown
- 2020-09-02 HR HRP20230230TT patent/HRP20230230T1/hr unknown
- 2020-09-02 PT PT207683988T patent/PT3877395T/pt unknown
- 2020-09-02 CU CU2022000013A patent/CU24692B1/es unknown
- 2020-09-02 AU AU2020343497A patent/AU2020343497B2/en active Active
- 2020-09-02 WO PCT/IB2020/058148 patent/WO2021044302A1/fr not_active Ceased
- 2020-09-02 LT LTEPPCT/IB2020/058148T patent/LT3877395T/lt unknown
- 2020-09-02 DK DK20768398.8T patent/DK3877395T3/da active
- 2020-09-02 MA MA54200A patent/MA54200B1/fr unknown
- 2020-09-02 FI FIEP20768398.8T patent/FI3877395T3/fi active
- 2020-09-02 JP JP2022511285A patent/JP7265087B2/ja active Active
- 2020-09-02 MX MX2022002603A patent/MX2022002603A/es unknown
- 2020-09-02 MY MYPI2022000866A patent/MY206905A/en unknown
- 2020-09-02 RS RS20230112A patent/RS63966B1/sr unknown
- 2020-09-02 PE PE2022000348A patent/PE20221418A1/es unknown
2022
- 2022-02-21 JO JOP/2022/0041A patent/JOP20220041A1/ar unknown
- 2022-02-28 CL CL2022000492A patent/CL2022000492A1/es unknown
- 2022-03-24 EC ECSENADI202222403A patent/ECSP22022403A/es unknown
- 2022-03-28 ZA ZA2022/03557A patent/ZA202203557B/en unknown
- 2022-03-29 CO CONC2022/0003769A patent/CO2022003769A2/es unknown
- 2022-09-02 PH PH1/2022/550388A patent/PH12022550388A1/en unknown

Also Published As

Publication number	Publication date
JP7265087B2 (ja)	2023-04-25
CA3147815A1 (fr)	2021-03-11
PH12022550388A1 (en)	2024-01-29
CU20220013A7 (es)	2022-10-11
KR20220071206A (ko)	2022-05-31
US20220296609A1 (en)	2022-09-22
GEP20247626B (en)	2024-05-27
ZA202203557B (en)	2022-11-30
JOP20220041A1 (ar)	2023-01-30
CL2022000492A1 (es)	2023-03-10
LT3877395T (lt)	2023-02-27
FI3877395T3 (fi)	2023-03-18
CN114302889B (zh)	2023-08-29
NZ786568A (en)	2026-01-30
CU24692B1 (es)	2024-01-10
PL3877395T3 (pl)	2023-05-08
MX2022002603A (es)	2022-03-25
BR112022003254A2 (pt)	2022-05-17
ES2855923T1 (es)	2021-09-24
CN114302889A (zh)	2022-04-08
JP2022546016A (ja)	2022-11-02
SI3877395T1 (sl)	2023-03-31
PE20221418A1 (es)	2022-09-20
ECSP22022403A (es)	2022-04-29
PT3877395T (pt)	2023-02-02
IL290973A (en)	2022-05-01
RS63966B1 (sr)	2023-03-31
EP3877395A1 (fr)	2021-09-15
HUE061427T2 (hu)	2023-07-28
HU231240B1 (hu)	2022-04-28
HRP20230230T1 (hr)	2023-04-14
WO2021044302A1 (fr)	2021-03-11
US11633406B2 (en)	2023-04-25
MY206905A (en)	2025-01-15
KR102871606B1 (ko)	2025-10-16
MA54200B1 (fr)	2023-02-28
IL290973B2 (en)	2023-11-01
CO2022003769A2 (es)	2022-04-19
MD3877395T2 (ro)	2023-05-31
AU2020343497B2 (en)	2023-02-02
IL290973B1 (en)	2023-07-01
CA3147815C (fr)	2023-03-28
EP3877395B1 (fr)	2022-12-07
ES2855923T3 (es)	2023-04-28
AU2020343497A1 (en)	2022-04-14
HUP1900315A1 (hu)	2021-03-29
DK3877395T3 (da)	2023-03-06

Publication	Publication Date	Title
MA54200A (fr)	2022-04-27	Procédé industriel pour la préparation d'estétrol de pureté élevée
EP3856941A4 (fr)	2022-06-15	Procédé pour la préparation d'un sulfate de nickel hydraté de haute pureté
EP3941924A4 (fr)	2022-12-28	Technologies utiles pour la préparation d'oligonucléotides
MA50859A (fr)	2020-09-09	Procédé pour la production d'une composition de lymphocytes t
MA49700A (fr)	2021-03-17	Procédé amélioré pour la préparation de dérivés d'aminopyrimidine
EP4306505A4 (fr)	2025-01-15	Procédé de préparation de 1,1,2-trifluoroéthane
EP3901133A4 (fr)	2022-10-05	Procédé de préparation de diisocyanate d'isophorone
EP4015519A4 (fr)	2023-07-12	Procédé de préparation d'asénapine
MA45768A (fr)	2019-06-05	Procédé pour la préparation de compositions d'immunoglobulines
EP3645529A4 (fr)	2021-03-10	Procédé pour la préparation de lifitegrast et d'intermédiaires de celui-ci
EP3613727A4 (fr)	2020-05-27	Procédé de préparation pour la coproduction de composés d'acrylamide et de formamide
EP3658553A4 (fr)	2021-04-21	Nouveaux intermédiaires utiles pour la synthèse de dérivés d'aminopyrimidine, leur procédé de préparation et procédé de préparation de dérivés d'aminopyrimidine à l'aide de ceux-ci
EP3768487A4 (fr)	2021-11-24	Procédé de micromoulages d'articles
EP3733648A4 (fr)	2021-07-07	Procédé de préparation d'acide 5r-benzyloxyaminopipéridin-2s-carboxylique ou d'un dérivé de celui-ci
EP3770280A4 (fr)	2021-01-27	Procédé pour la fabrication d'acier de haute pureté
EP3874056C0 (fr)	2023-06-14	Procédé enzymatique de préparation d'udp-glcnac
EP3788027A4 (fr)	2022-03-09	Procédé à recirculation pour la préparation d'éthylène glycol
EP4021920A4 (fr)	2023-08-16	Procédé amélioré pour la préparation de chlorhydrate d'ételcalcétide
EP3644335A4 (fr)	2020-05-13	Procédé de préparation d'un matériau actif d'anode pour pseudo-condensateur
EP3889572A4 (fr)	2021-11-24	Procédé de préparation d'échantillon
MA51870A (fr)	2020-10-07	Procédé pour la préparation de composés coupleurs de médicaments
EP3927678A4 (fr)	2022-10-26	Procédé de séparation de produits d'oligomérisation oléfiniques (variants)
EP3663322A4 (fr)	2021-01-20	Procédé de préparation d'oligomère de butène
EP4201524A4 (fr)	2024-12-18	Procédé de production d'oléfines
EP3515915A4 (fr)	2020-05-27	Procédé de préparation d'intermédiaires d'hydroxyurée inhibiteurs des bêta-lactamases